Prepregnancy Dopamine Agonist Treatment Duration as a Predictor of Postpartum Prolactinoma Remission
Authors' conclusion
Pregnancy itself did not influence the long-term prolactinoma remission. Instead, sustained postpartum remission was associated with at least 48 months of DA therapy before conception, highlighting the importance of adequate treatment duration prior to pregnancy.
Study context
- Population
- Women with prolactinoma treated 2003–2024matched 1:2
- Participants
- 225 women
- Exposure
- Pregnancy during dopamine agonist (DA) therapy vs nonpregnant controls
- Pregnancyn = 75
- Nonpregnant controlsn = 150reference
- Outcome
- Prolactinoma remission
- Follow-up
- Last
Methodological detailspropensity score matched 1:2
- Propensity score matched 1:2
Main finding
As reported in the abstract
Final remission rate · last follow-up (median 110.0 months for pregnancy group)
P = 0.342
- Pregnancy not associated with prolactinoma remission in overall cohort
- P = 0.576
Observational data: associations, not effects.
Further findings
Predictor of remission among pregnant women: prepregnancy DA duration >48 months
- OR (only significant independent predictor)
- 4.48 (95% CI 1.31-15.36; P = .017)
Recurrence-free probability by prepregnancy DA duration (Kaplan-Meier)
- Significantly higher with >48 months before conception
- P = 0.020
- 36-month threshold not significant
- P = 0.103
Original publication
Prepregnancy Dopamine Agonist Treatment Duration as a Predictor of Postpartum Prolactinoma Remission. Endocr Pract. Published 18 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →